bluebird bio Inc
NASDAQ:BLUE
bluebird bio Inc
Short-Term Investments
bluebird bio Inc
Short-Term Investments Peer Comparison
Competitive Short-Term Investments Analysis
Latest Figures & CAGR of Competitors
Company | Short-Term Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
bluebird bio Inc
NASDAQ:BLUE
|
Short-Term Investments
$8.9m
|
CAGR 3-Years
-79%
|
CAGR 5-Years
-59%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Short-Term Investments
$2m
|
CAGR 3-Years
-55%
|
CAGR 5-Years
-64%
|
CAGR 10-Years
-46%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Short-Term Investments
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Amgen Inc
NASDAQ:AMGN
|
Short-Term Investments
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Short-Term Investments
$1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
12%
|
CAGR 10-Years
1%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Short-Term Investments
$7.9B
|
CAGR 3-Years
56%
|
CAGR 5-Years
39%
|
CAGR 10-Years
46%
|
See Also
What is bluebird bio Inc's Short-Term Investments?
Short-Term Investments
8.9m
USD
Based on the financial report for Sep 30, 2023, bluebird bio Inc's Short-Term Investments amounts to 8.9m USD.
What is bluebird bio Inc's Short-Term Investments growth rate?
Short-Term Investments CAGR 5Y
-59%
Over the last year, the Short-Term Investments growth was -88%. The average annual Short-Term Investments growth rates for bluebird bio Inc have been -79% over the past three years , -59% over the past five years .